Page 2 - Read Online
P. 2

Topic: Treatment of

                                                           Pancreatic Cancer




                                                           Pancreatic cancer is an increasingly common
                                                           malignancy  that  has  benefited  very  little  from
                                                           research  advancements  and  new  discoveries,  as  it
                                                           remains largely an untreatable disease with a 5-year
                                                           survival  rate  lower  than  9%.  The  reasons  for  this
                                                           setback  are  searched  in  the  lack  of  specific  early-

                        Marco Falasca                      stage  symptomatology,  leading  to  a  late  diagnosis
                                                           and  consequently  limited  option  of  treatment,  as
              Prof Marco Falasca has over 30 year-         well  as  resistance  to  chemo-  and  radiotherapy  and
              experience and a track record in signal      high metastatic potential. Disruption of cell signaling
              transduction in cancer cells. He has worked   pathways and genetic alterations involving activation
              in international renowned institutions such   of oncogenes and blocking of tumor suppressors are
              as New York University, University College   well known to contribute to the start and progression
              London and Queen Mary University of          of  this  tumor.  Yet,  new  understanding  and  insight,
              London. His achievements include highly      particularly  guiding  towards  new  strategies  for
              cited publications in top journals such as   improved therapies, is eagerly awaited. This Special
              Science, Nature Communications, EMBO
              J, PNAS, supported by competitive grants     Issue  intends  to  publish  original  research,  expert
              and industry sources. He has made seminal    opinions,  and  reviews  on  basic,  translational  and
              and significant contributions including:     clinical  studies  connected  to  different  aspects  of
              pioneering work on the biological activity and   pancreatic  cancer  cell  biology,  genomics,  precision
              signalling properties of the lysophospholipid   medicine,  medical  oncology,  radiation  therapy,  and
              lysophosphatidylinositol (LPI); he was       surgery.
              among the very first to demonstrate the
              ability of pleckstrin homology domains to
              bind phosphoinositides; he also identified a
              novel signalling role for the phosphoinositide
              phosphatidylinositol-3-monophosphate (PI3P)
              and in parallel he identified class II PI3K as
              the enzymes responsible for the production of
              PI3P unravelling a novel functional role for
              this class of enzymes.
   1   2   3   4   5   6   7